Roche logo

Roche launches a global network of cancer immunotherapy centers of research excellence (imCORE™)

15 November 2016 Roche has launched the global network of cancer immunotherapy Centers of Research Excellence (imCORE™), which will bring together many of the world’s leading scientific and clinical experts in cancer immunotherapy for collaborating in the investigation of the most promising new treatment approaches. The target is to start pre-clinical and clinical research rapidly … Continue reading Roche launches a global network of cancer immunotherapy centers of research excellence (imCORE™)

Amgen and Advaxis Enter Global Cancer Immunotherapies Collaboration

Aug. 2, 2016 Amgen and Advaxis, Inc. have announced a global agreement for the development and commercialization of Advaxis' ADXS-NEO. It is a novel, preclinical investigational cancer immunotherapy treatment that is designed to activate the immune system of a patient to respond against the unique mutations, or neoepitopes, contained in and identified from the tumor of … Continue reading Amgen and Advaxis Enter Global Cancer Immunotherapies Collaboration

Roche logo

Roche updates on phase III study of Gazyva/Gazyvaro in people with previously untreated diffuse large B-cell lymphoma

18 July 2016 Roche has announced that the phase III GOYA study that evaluates Gazyva®/Gazyvaro® (obinutuzumab) plus CHOP chemotherapy (G-CHOP) in people with previously untreated diffuse large B-cell lymphoma (DLBCL) did not meet its primary endpoint to significantly reduce the risk of disease worsening or death compared to MabThera/Rituxan (rituximab) plus CHOP chemotherapy (R-CHOP). It … Continue reading Roche updates on phase III study of Gazyva/Gazyvaro in people with previously untreated diffuse large B-cell lymphoma

Bristol-Myers Squibb and PsiOxus Therapeutics Declare Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Opdivo and Enadenotucirev

June 30, 2016 Bristol-Myers Squibb Company and PsiOxus Therapeutics, Ltd. have announced an exclusive clinical collaboration agreement for evaluating the tolerability, safety, and preliminary efficacy of Bristol-Myers Squibb’s Immuno-Oncology (I-O) agent Opdivo (nivolumab), in combination with PsiOxus’ enadenotucirev, a systemically administered oncolytic adenovirus therapeutic, to treat a range of tumor types in late-stage cancer patients. “This collaboration continues … Continue reading Bristol-Myers Squibb and PsiOxus Therapeutics Declare Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Opdivo and Enadenotucirev

Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals

July 5, 2016 Bristol-Myers Squibb Company and Cormorant Pharmaceuticals have announced that Bristol-Myers Squibb has acquired all of the outstanding capital stock of Cormorant, which is a private, Stockholm, Sweden-based pharmaceutical company that focuses on the development of therapies for cancer and rare diseases. This acquisition allows Bristol-Myers Squibb gain full rights to Cormorant’s HuMax-IL8 … Continue reading Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals

Amgen Logo

New Results from Pivotal Phase 3 Studies Show that Kyprolis® (Carfilzomib) Allows Patients with Relapsed Multiple Myeloma to Live Longer

June 10, 2016 Amgen has announced results from a post-hoc analysis of the pivotal Phase 3 ASPIRE study which emphasized the advantages of continued treatment with Kyprolis® (carfilzomib) in combination with lenalidomide and dexamethasone (KRd) in patients with relapsed multiple myeloma. Furthermore, separate sub-analyses of the Phase 3 ENDEAVOR study confirmed depth and efficacy of response benefits … Continue reading New Results from Pivotal Phase 3 Studies Show that Kyprolis® (Carfilzomib) Allows Patients with Relapsed Multiple Myeloma to Live Longer

Amgen Logo

BLINCYTO® (Blinatumomab) Improved Overall Survival in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia

June 10, 2016 Amgen has announced new data from an interim analysis of the Phase 3 TOWER study, in which BLINCYTO® (blinatumomab) confirmed nearly two-fold increase in median overall survival (OS) compared to standard of care (SOC). The randomized, open-label TOWER study estimated the effectiveness of BLINCYTO versus SOC chemotherapy in adult patients with Philadelphiachromosome-negative (Ph-) relapsed or … Continue reading BLINCYTO® (Blinatumomab) Improved Overall Survival in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia

Celgene and Acceleron Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes

Jun 10, 2016 Celgene Corporation and Acceleron Pharma Inc. has announced preliminary results from an ongoing long-term Phase 2 extension study with luspatercept in patients with lower risk myelodysplastic syndromes (MDS). Results were declared at the 21st Congress of the European Hematology Association (EHA) in Copenhagen, Denmark. Results of the study showed that 51% of patients with lower risk MDS treated … Continue reading Celgene and Acceleron Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes

BMS logo

European Commission Approves the Immuno-Oncology Combination, Opdivo® (nivolumab) + Yervoy® (ipilimumab) Regimen of Bristol-Myers Squibb, for Treatment of Advanced Melanoma

May 11, 2016 Bristol-Myers Squibb Company has announced that the European Commission (EC) has approved Opdivo in combination with Yervoy for treating advanced (unresectable or metastatic) melanoma in adults. This combination represents the first and only approved combination of two Immuno-Oncology agents in the European Union (EU). Due to this approval, it has become legitimate to market Opdivo + Yervoy Regimen in … Continue reading European Commission Approves the Immuno-Oncology Combination, Opdivo® (nivolumab) + Yervoy® (ipilimumab) Regimen of Bristol-Myers Squibb, for Treatment of Advanced Melanoma

Amgen Logo

FDA Grants Priority Review for Supplemental Biologics License Application of Amgen for BLINCYTO® (Blinatumomab)

May 3, 2016  Amgen has announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental Biologics License Application (sBLA) for BLINCYTO® (blinatumomab) for including new data supporting the treatment of adolescent and pediatric patients with Philadelphia chromosome‑negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). "Children and adolescents with ALL who experience a … Continue reading FDA Grants Priority Review for Supplemental Biologics License Application of Amgen for BLINCYTO® (Blinatumomab)